Evercore ISI reiterates Boston Scientific stock rating on growth outlook By Investing.com

Evercore ISI reiterated an Outperform on Boston Scientific with a $96 price target vs. the current share price of $69.54 (implying ~27% upside) and an InvestingPro Fair Value of $78.23 (~12.5% upside). Evercore expects ~9% revenue CAGR through 2028, noted a PEG of 0.65 and current P/E of 35.94, and flagged the CHAMPION AF trial readout and an ACC presentation in March 2026 as key catalysts. Multiple other brokers reiterated Buy or Hold price targets ($90 Stifel, $92 Truist, $120 Jefferies, $100 TD Cowen) and the company added two board members (Cathy Smith, Christophe Weber), supporting a constructive near-term narrative for the stock.

Analysis

A successful near-term clinical readout that expands indications would not only increase unit demand but also re-rate the company’s ability to capture higher-margin procedural spend inside cardiology labs. Expect hospitals and integrated delivery networks to negotiate volume-based pricing and bundled payments; a 5–10% incremental market-share gain in structural heart devices can translate into low‑hundreds of millions of incremental revenue over 12–24 months because implantable device economics concentrate value at scale.

Second-order winners include imaging and cath‑lab consumables suppliers (more procedures → higher recurring disposables) while legacy anticoagulant makers and electrophysiology mapping vendors face slower growth if device therapy displaces drug-first pathways. Reimbursement cadence is the gating factor: a positive clinical outcome can take 6–18 months to fully convert into wider payer coverage and hospital protocol changes, so near-term price moves may overshoot fundamentals in either direction.

Tail risks are binary clinical/regulatory surprises and execution against a heavy product pipeline; a negative safety signal or missed operational milestones could compress multiples sharply within days, whereas steady execution and visible share gains should compress perceived execution risk and support multiple expansion over 12–36 months. Monitoring procedure volumes, CMS/local payer coding updates, and 8–12 week post-readout hospital adoption data will be the earliest high‑signal indicators for durable demand shifts.

Key Decisions for Investors

• Tactical long (high conviction): Buy BSX shares sized 1–2% NAV on a readout miss/overreaction dip; target 30–50% upside over 9–18 months if adoption data and payer signals align. Use a protective 15% trailing stop or buy 12–18 month puts 10–12% out-of-the-money to cap downside to ~10–12% net cost.
• Event options (asymmetric): Buy BSX Jan 2027 LEAP calls (roughly 12–18 months) at a strike ~15% above current price for 1–2% NAV exposure; upside >2x if multiple re‑rating occurs, limited premium loss if readout fails.
• Pair trade (risk‑managed): Long BSX / Short MDT or ABT (equal notional) for 6–12 months to isolate device-specific clinical risk from broader medtech cyclicality; if BSX outperforms by >20% relative in 12 months, trim to half position.
• Income/collar for conservative holders: Sell 3–6 month BSX covered calls at ~10% out and buy 3–6 month puts at ~10% down to create a collar that generates premium and limits downside to ~10% while forgoing small near-term upside.
• Risk cut trigger: If post‑readout hospital adoption surveys show <5% lift in procedure volumes at top 50 accounts within 6 months, reduce directional exposure by 50% — clinical readouts without adoption are value traps.